Medicamen Biotech Limited Share Price & Analysis
₹270.25+4.18%Updated 4 Sept 2026, 03:30 pm IST
LTP
₹270.25+4.18%Open
₹258.00High
₹276.75Low
₹258.00Close
₹270.2552W High
₹454.0052W Low
₹210.00Volume
118KLot Size
1Sector
HealthcareMarket Cap
₹367 CrFace Value
₹10Small Cap
Price Chart
Candle
Range
Fundamentals
P/E
33.80Sector P/E
54.70P/B
1.17EPS
₹7.06ROE
3.95%ROCE
5.43%D/E Ratio
0.17Div Yield
0.37%Book Value
₹203.00Strengths
- Attractively valued vs sector (P/E 33.8x vs industry 54.7x)
- Low debt relative to equity (D/E 0.2x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MEDICAMEQ · as of Mar 2026
Promoters43.16%0.17pp
FII0.12%0.06pp
DII0.69%0.18pp
Public55.99%0.05pp
Govt0.06%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.21% | 43.21% | 42.99% | 42.99% | 42.99% | 43.16% |
| FII | 0.22% | 0.12% | 0.06% | 0.06% | 0.06% | 0.12% |
| DII | 0.67% | 0.99% | 1.17% | 1.17% | 0.87% | 0.69% |
| Public | 55.90% | 55.69% | 55.78% | 55.79% | 56.04% | 55.99% |
| Govt | — | — | — | — | 0.06% | 0.06% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend26 May 2026
Dividend - Re 1 Per Share
Dividend18 Sept 2025
Annual General Meeting/Dividend - Re 1 Per Share
Dividend18 Sept 2024
Annual General Meeting/Dividend - Re 1 Per Share
Dividend19 Sept 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹46.91 Cr 0.6% | ₹47.17 Cr 9.6% | ₹43.04 Cr 45.4% | ₹29.61 Cr 34.4% | ₹45.14 Cr 0.9% | ₹44.74 Cr 3.9% | ₹43.05 Cr 9.0% | ₹47.32 Cr |
| Op. Profit | ₹4.38 Cr 15.1% | ₹5.16 Cr 11.9% | ₹4.61 Cr 386.3% | ₹-1.61 Cr 124.0% | ₹6.71 Cr 26.4% | ₹5.31 Cr 53.9% | ₹3.45 Cr 40.0% | ₹5.75 Cr |
| OPM | 9.3% 14.6% | 10.9% 2.1% | 10.7% 296.9% | -5.4% 136.6% | 14.9% 25.2% | 11.9% 48.2% | 8.0% 34.1% | 12.2% |
| Net Profit | ₹1.64 Cr 22.6% | ₹2.12 Cr 32.5% | ₹1.6 Cr 14.4% | ₹1.87 Cr 36.0% | ₹2.92 Cr 220.9% | ₹0.91 Cr 13.7% | ₹0.8 Cr 60.8% | ₹2.04 Cr |
| EPS (₹) | 1.61 18.3% | 1.97 23.9% | 1.59 16.3% | 1.9 30.4% | 2.73 137.4% | 1.15 8.5% | 1.06 36.9% | 1.68 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹198 Cr 21.5% | ₹163 Cr 8.9% | ₹179 Cr 27.0% | ₹141 Cr 22.6% | ₹115 Cr 1.8% | ₹113 Cr 9.6% | ₹125 Cr 1.6% | ₹123 Cr |
| Expenses | ₹178 Cr 20.3% | ₹148 Cr 5.1% | ₹156 Cr 33.3% | ₹117 Cr 28.6% | ₹91 Cr 2.2% | ₹93 Cr 12.3% | ₹106 Cr 1.0% | ₹105 Cr |
| Op. Profit | ₹20 Cr 42.9% | ₹14 Cr 41.7% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 20.0% | ₹20 Cr 0.0% | ₹20 Cr 17.6% | ₹17 Cr |
| OPM | 10.0% 11.1% | 9.0% 30.8% | 13.0% 23.5% | 17.0% 19.0% | 21.0% 23.5% | 17.0% 6.3% | 16.0% 14.3% | 14.0% |
| Other Income | ₹3 Cr 50.0% | ₹6 Cr 200.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 50.0% | ₹4 Cr |
| Interest | ₹4 Cr 0.0% | ₹4 Cr 33.3% | ₹6 Cr 100.0% | ₹3 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 100.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Depreciation | ₹7 Cr 0.0% | ₹7 Cr 0.0% | ₹7 Cr 16.7% | ₹6 Cr 0.0% | ₹6 Cr 100.0% | ₹3 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr |
| PBT | ₹12 Cr 20.0% | ₹10 Cr 23.1% | ₹13 Cr 23.5% | ₹17 Cr 5.6% | ₹18 Cr 12.5% | ₹16 Cr 11.1% | ₹18 Cr 0.0% | ₹18 Cr |
| Tax % | 18.0% 47.1% | 34.0% 25.9% | 27.0% 92.9% | 14.0% 22.2% | 18.0% 30.8% | 26.0% 0.0% | 26.0% 16.1% | 31.0% |
| Net Profit | ₹10 Cr 42.9% | ₹7 Cr 22.2% | ₹9 Cr 40.0% | ₹15 Cr 0.0% | ₹15 Cr 25.0% | ₹12 Cr 7.7% | ₹13 Cr 8.3% | ₹12 Cr |
| EPS (₹) | 7.11 27.2% | 5.59 35.0% | 8.6 26.7% | 11.73 3.9% | 12.2 22.9% | 9.93 8.7% | 10.88 5.8% | 10.28 |
| Div Payout | 14.0% 22.2% | 18.0% 50.0% | 12.0% 33.3% | 9.0% 12.5% | 8.0% 20.0% | 10.0% 100.0% | 5.0% 50.0% | 10.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹14 Cr 0.0% | ₹14 Cr 7.7% | ₹13 Cr 0.0% | ₹13 Cr 0.0% | ₹13 Cr 8.3% | ₹12 Cr 0.0% | ₹12 Cr 0.0% | ₹12 Cr 0.0% | ₹12 Cr |
| Reserves | ₹262 Cr 0.0% | ₹262 Cr 31.0% | ₹200 Cr 3.1% | ₹194 Cr 7.2% | ₹181 Cr 35.1% | ₹134 Cr 10.7% | ₹121 Cr 11.0% | ₹109 Cr 45.3% | ₹75 Cr |
| Borrowings | ₹48 Cr 23.1% | ₹39 Cr 14.7% | ₹34 Cr 9.7% | ₹31 Cr 19.2% | ₹26 Cr 0.0% | ₹26 Cr 36.8% | ₹19 Cr 72.7% | ₹11 Cr 8.3% | ₹12 Cr |
| Other Liabilities | ₹49 Cr 7.5% | ₹53 Cr 6.0% | ₹50 Cr 10.7% | ₹56 Cr 5.1% | ₹59 Cr 11.3% | ₹53 Cr 26.2% | ₹42 Cr 14.3% | ₹49 Cr 28.9% | ₹38 Cr |
| Total Liabilities | ₹372 Cr 1.4% | ₹367 Cr 23.6% | ₹297 Cr 0.7% | ₹295 Cr 5.7% | ₹279 Cr 23.5% | ₹226 Cr 16.5% | ₹194 Cr 7.2% | ₹181 Cr 32.1% | ₹137 Cr |
Assets | |||||||||
| Fixed Assets | ₹85 Cr 1.2% | ₹86 Cr 1.1% | ₹87 Cr 5.4% | ₹92 Cr 1.1% | ₹93 Cr 1.1% | ₹92 Cr 2.2% | ₹90 Cr 164.7% | ₹34 Cr 41.7% | ₹24 Cr |
| CWIP | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹40 Cr 166.7% | ₹15 Cr |
| Investments | ₹0 Cr 100.0% | ₹8 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹287 Cr 5.1% | ₹273 Cr 30.0% | ₹210 Cr 3.4% | ₹203 Cr 9.1% | ₹186 Cr 39.8% | ₹133 Cr 27.9% | ₹104 Cr 2.8% | ₹107 Cr 10.3% | ₹97 Cr |
| Total Assets | ₹372 Cr 1.4% | ₹367 Cr 23.6% | ₹297 Cr 0.7% | ₹295 Cr 5.7% | ₹279 Cr 23.5% | ₹226 Cr 16.5% | ₹194 Cr 7.2% | ₹181 Cr 32.1% | ₹137 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | — | ₹-8 Cr 14.3% | ₹-7 Cr 16.7% | ₹-6 Cr 250.0% | ₹4 Cr 69.2% | ₹13 Cr 0.0% | ₹13 Cr 225.0% | ₹4 Cr |
| Investing CF | — | ₹-1 Cr 83.3% | ₹-6 Cr 0.0% | ₹-6 Cr 25.0% | ₹-8 Cr 55.6% | ₹-18 Cr 51.4% | ₹-37 Cr 146.7% | ₹-15 Cr |
| Financing CF | — | ₹-1 Cr 116.7% | ₹6 Cr 79.3% | ₹29 Cr 625.0% | ₹4 Cr 33.3% | ₹6 Cr 68.4% | ₹19 Cr 575.0% | ₹-4 Cr |
| Net Cash Flow | — | ₹-11 Cr 83.3% | ₹-6 Cr 135.3% | ₹17 Cr | ₹0 Cr 100.0% | ₹1 Cr 120.0% | ₹-5 Cr 64.3% | ₹-14 Cr |
| Free Cash Flow | — | ₹-10 Cr 23.1% | ₹-13 Cr 0.0% | ₹-13 Cr 225.0% | ₹-4 Cr 20.0% | ₹-5 Cr 80.0% | ₹-25 Cr 127.3% | ₹-11 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 151d 2.6% | 155d 38.4% | 112d 33.7% | 169d 15.5% | 200d 17.6% | 170d 17.2% | 145d 12.4% | 129d |
| Inventory Days | 251d 6.3% | 268d 14.5% | 234d 2.6% | 228d 21.3% | 188d 596.3% | 27d 65.4% | 78d 16.4% | 67d |
| Days Payable | 144d 21.7% | 184d 19.5% | 154d 36.1% | 241d 20.2% | 302d 78.7% | 169d 2.3% | 173d 29.1% | 134d |
| Cash Conv. Cycle | 259d 8.4% | 239d 23.8% | 193d 23.7% | 156d 81.4% | 86d 207.1% | 28d 45.1% | 51d 17.7% | 62d |
| Working Capital Days | 193d 3.8% | 186d 51.2% | 123d 21.2% | 156d 6.1% | 147d 16.7% | 126d 3.1% | 130d 12.1% | 116d |
| ROCE | 5.0% 16.7% | 6.0% 25.0% | 8.0% 20.0% | 10.0% 16.7% | 12.0% 7.7% | 13.0% 18.8% | 16.0% | — |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Medicamen Biotech Limited share price today?
Medicamen Biotech Limited (MEDICAMEQ) is currently trading at ₹270.25 on NSE, up 4.18% as of the last market session. Prices update daily after market close on MarketNetra.
Is Medicamen Biotech Limited available in F&O (Futures & Options)?
Yes, Medicamen Biotech Limited (MEDICAMEQ) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Medicamen Biotech Limited 52-week high and low?
Medicamen Biotech Limited's 52-week high is ₹454 and the 52-week low is ₹210. The current price of ₹270.25 is 40.5% below the 52W high.
What is Medicamen Biotech Limited P/E ratio?
Medicamen Biotech Limited's current P/E ratio is 33.8. This indicates the market is paying ₹33.8 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Medicamen Biotech Limited options?
Medicamen Biotech Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MEDICAMEQ options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.